FDA rushed to approve new drugs in 2019, sometimes way ahead of schedule. Could that be dangerous?
While the roster of 48 drugs (plus 4 notable biologics) the FDA approved in 2019 didn’t break any records with the sheer number it was remarkable in one aspect: The agency reached deep into a group of therapies they didn’t need to make a decision on until later this year, in some cases speeding drugs up by months ahead of even priority review deadlines.
On the surface, that’s great news for drugmakers and the patients they hope to help. But according to a recent study on rushed approvals, it could also spell safety troubles down the road.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.